You are here
Press Release Archive
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 27, 2015.
Merck KGaA, Darmstadt, Germany and Pfizer today announced that six abstracts on studies evaluating the potential role of programmed death-ligand 1 (PD-L1) inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab* will be presented at this year’s ECC in Vienna, Austria, September 25–29, 2015.
Pfizer Inc. ("Pfizer") (NYSE:PFE) announced today that it has commenced offers to exchange any and all validly tendered and accepted notes of the following series issued by Hospira, Inc. ("Hospira"), our recently acquired subsidiary, for new notes to be issued by Pfizer as described in the table below.
Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Hospira, Inc.
The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. today announced the launch of the Palbociclib Collaborative AdjuvantStudy, or PALLAS.
Pfizer Inc. today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Hospira.
Pfizer Inc. (NYSE:PFE) announced today positive topline results of two Phase 3 studies of TRUMENBA® (Meningococcal Group B Vaccine).
Pfizer Inc. today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for IBRANCE® (palbociclib) in combination with endocrine therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.
Pfizer Inc. (NYSE: PFE) today announced that it was granted approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira (NYSE: HSP). As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada.
Pfizer Inc. (NYSE:PFE) today announced that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Hospira, Inc. (NYSE:HSP) and found no need for remedies.
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company’s pending acquisition of Hospira, Inc. (NYSE: HSP).
Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).
Pfizer announced today the expansion of its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus in Kendall Square (KSQ).
Pfizer’s Centers for Therapeutic Innovation (CTI) and the Jeffrey Modell Foundation (JMF) announced today a collaboration agreement to conduct research in the field of immunological diseases.
Pfizer Inc. (NYSE: PFE) announced today enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery.
Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) accepted for review Pfizer’s new drug application (NDA) for XELJANZ® (tofacitinib citrate) 11 mg once daily modified release tablets for the treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX).
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.
Current Stock Price
|%Change||.||52 Wk. High||.|
|Day High||.||52 Wk. Low||.|
|Day Low||.||Mkt. Cap(Mil)||.|
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.